NANOBIOTIX Provides First Half 2026 Operational and Financial Update

September 25, 2026 - 00:58

Nanobiotix has released its operational and financial update for the first half of 2026, highlighting progress across its clinical programs and a significantly improved financial standing.

The company reported promising early results from the full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study. This trial evaluated JNJ-1900, also known as NBTXR3, in patients with inoperable, locoregionally recurrent non-small cell lung cancer who are candidates for re-irradiation. According to the update, the treatment has shown an acceptable safety profile along with promising initial efficacy responses, offering a potential new option for this difficult-to-treat patient population.

On the financial side, Nanobiotix strengthened its position through an oversubscribed global follow-on offering that raised approximately 86 million euros in May 2026. This capital infusion extends the company's cash runway into 2029, providing the resources needed to advance its clinical pipeline and support ongoing research and development activities.

The combination of encouraging clinical data and a solid financial foundation positions the company to continue its work in developing innovative radioenhancer therapies for cancer patients with limited treatment options. Further analysis and trial progression are expected in the coming months.